Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
|Articles|July 26, 2018
Supplements and Featured Publications
- Exclusive Coverage of the American Society of Clinical Oncology Annual Meeting
Exclusive Coverage of the 2018 American Society of Clinical Oncology Annual Meeting
Advertisement
Highlights from the American Society of Clinical Oncology meeting, which took place on June 1-5, 2018 in Chicago, IL are available in this newsletter published by The American Journal of Managed Care.
Advertisement
Related to this article
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
PBM Reform and Supportive Care Needs: Nicolas Ferreyros
4
Genetic Analysis Links Insomnia Liability to Higher Inflammation Marker
5